Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 3
2019 3
2020 4
2021 2
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Citations

2 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD; Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators. Vardeny O, et al. Eur J Heart Fail. 2016 Oct;18(10):1228-1234. doi: 10.1002/ejhf.580. Epub 2016 Jun 10. Eur J Heart Fail. 2016. PMID: 27283779 Free PMC article. Clinical Trial.
AIMS: In this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril. MET …
AIMS: In this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during t …
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Velazquez EJ, et al. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. N Engl J Med. 2019. PMID: 30415601 Clinical Trial.
RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsarta …
RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive …
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
Chatur S, Claggett BL, McCausland FR, Rouleau J, Zile MR, Packer M, Pfeffer MA, Lefkowitz M, McMurray JJV, Solomon SD, Vaduganathan M. Chatur S, et al. J Am Coll Cardiol. 2023 Apr 18;81(15):1443-1455. doi: 10.1016/j.jacc.2023.02.009. Epub 2023 Feb 20. J Am Coll Cardiol. 2023. PMID: 36812948 Free article.
METHODS: In sequential run-in phases, patients were titrated to enalapril 10 mg twice daily and then sacubitril/valsartan 97 mg/103 mg twice daily (in PARADIGM-HF) or valsartan 80 mg twice daily and then sacubitril/valsartan 49 mg/51 mg twice da …
METHODS: In sequential run-in phases, patients were titrated to enalapril 10 mg twice daily and then sacubitril/valsartan …
Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S. Jain AR, et al. Indian Heart J. 2020 Nov-Dec;72(6):535-540. doi: 10.1016/j.ihj.2020.09.016. Epub 2020 Sep 28. Indian Heart J. 2020. PMID: 33357641 Free PMC article. Clinical Trial.
OBJECTIVES: To determine efficacy and safety of sacubitril/valsartan compared with enalapril in Indian patients of PARADIGM-HF trial. ...The all-cause mortality (19.0% vs. 21.9%) and adverse events (78.4% vs. 82.2%) were comparatively low …
OBJECTIVES: To determine efficacy and safety of sacubitril/valsartan compared with enalapril in Indian patients …
Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
Morrow DA, Velazquez EJ, Desai AS, DeVore AD, Lepage S, Park JG, Sharma K, Solomon SD, Starling RC, Ward JH, Williamson KM, Zieroth S, Hernandez AF, Mentz RJ, Braunwald E. Morrow DA, et al. J Am Coll Cardiol. 2024 Mar 26;83(12):1123-1132. doi: 10.1016/j.jacc.2024.01.027. J Am Coll Cardiol. 2024. PMID: 38508844 Free article. Clinical Trial.
METHODS: The PIONEER-HF and PARAGLIDE-HF trials were double-blind, randomized trials of sacubitril/valsartan vs control therapy (enalapril or valsartan, respectively). ...Cardiovascular death or hospitalization for HF was reduced by 30% with sacubit …
METHODS: The PIONEER-HF and PARAGLIDE-HF trials were double-blind, randomized trials of sacubitril/valsartan vs control …
Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction.
Yang P, Li X, Wang L, Wu X, Wang C, Li T, Wang H. Yang P, et al. Front Cardiovasc Med. 2023 Jan 13;9:1059420. doi: 10.3389/fcvm.2022.1059420. eCollection 2022. Front Cardiovasc Med. 2023. PMID: 36712243 Free PMC article.
Similarly, the PARADIGM-HF trial (Comparison of Sacubitril-Valsartan vs. Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode) came to similar conclusions and extended the PARADIGM-HF trial results in 2019. ...The …
Similarly, the PARADIGM-HF trial (Comparison of Sacubitril-Valsartan vs. Enalapril on Effect on NT-proBNP in Pat …
Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure.
Nakamura M, Imamura T, Joho S, Kinugawa K. Nakamura M, et al. Circ Rep. 2021 Sep 4;3(10):589-593. doi: 10.1253/circrep.CR-21-0068. eCollection 2021 Oct 8. Circ Rep. 2021. PMID: 34703936 Free PMC article.
Background: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has demonstrated survival benefit and reduces heart failure hospitalization compared with enalapril in patients with heart failure and reduced ejection fraction. ...Further evalua …
Background: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has demonstrated survival benefit and reduces …
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Vardeny O, et al. Circ Heart Fail. 2018 Apr;11(4):e004745. doi: 10.1161/CIRCHEARTFAILURE.117.004745. Circ Heart Fail. 2018. PMID: 29643067
Concern on hypotension may be limiting use of sacubitril/valsartan in appropriate patients. METHODS AND RESULTS: We characterized patients in PARADIGM-HF by whether they reported hypotension during study run-in periods (enalapril, followed by sacubitril …
Concern on hypotension may be limiting use of sacubitril/valsartan in appropriate patients. METHODS AND RESULTS: We characteri …
Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial.
Dong Y, Xu Y, Ding C, Yu Z, Yu Z, Xia X, Chen Y, Jiang X. Dong Y, et al. Cardiovasc Diagn Ther. 2022 Feb;12(1):42-54. doi: 10.21037/cdt-21-386. Cardiovasc Diagn Ther. 2022. PMID: 35282662 Free PMC article.
BACKGROUND: For patients with heart failure (HF), the effect of angiotensin receptor-neprilysin inhibitors (ARNIs, sacubitril/valsartan) on cardiac remodeling has been found to be superior to angiotensin-converting enzyme inhibitors (ACEI). ...RESULTS: We found that …
BACKGROUND: For patients with heart failure (HF), the effect of angiotensin receptor-neprilysin inhibitors (ARNIs, sacubitril/vals …
The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Mazza A, Townsend DM, Torin G, Schiavon L, Camerotto A, Rigatelli G, Cuppini S, Minuz P, Rubello D. Mazza A, et al. Biomed Pharmacother. 2020 Oct;130:110596. doi: 10.1016/j.biopha.2020.110596. Epub 2020 Aug 21. Biomed Pharmacother. 2020. PMID: 34321170 Free PMC article.
BACKGROUND: Sacubitril/valsartan, the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular mortality and morbidity compared to enalapril in outpatient subjects wi …
BACKGROUND: Sacubitril/valsartan, the first agent to be approved in a new class of drugs called angiotensin receptor neprilysi …
16 results